Global Icotinib Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Icotinib Market Insights, Forecast to 2034
Icotinib (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations.
Global Icotinib market is expected to reach to US$ 17 million in 2024, with a positive growth of %, compared with US$ 15 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Icotinib industry is evaluated to reach US$ 28 million in 2029. The CAGR will be 8.6% during 2024 to 2029.
The Icotinib market is primarily driven by the demand for targeted therapies in the treatment of non-small cell lung cancer (NSCLC). Icotinib is a medication used as a tyrosine kinase inhibitor for patients with advanced NSCLC that carries EGFR mutations. The increasing prevalence of lung cancer, particularly among non-smokers and those with specific genetic mutations, contributes to market growth. Moreover, advancements in personalized medicine and the demonstrated efficacy of Icotinib in improving progression-free survival further propel adoption. However, challenges include managing the cost of targeted therapies and addressing potential drug resistance or adverse effects. Navigating patient access issues, optimizing treatment sequencing, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in lung cancer treatment, collaborations between pharmaceutical manufacturers and oncologists, and comprehensive patient education on the benefits and potential risks of Icotinib treatment while addressing the evolving challenges associated with precision oncology and cancer treatment accessibility.
Report Covers
This report presents an overview of global Icotinib market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Icotinib market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Bette Pharma
Segment by Type
250mg
125mg
Hospital
Drugs Store
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Icotinib plant distribution, commercial date of Icotinib, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Icotinib introduction, etc. Icotinib Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Icotinib
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Icotinib market is expected to reach to US$ 17 million in 2024, with a positive growth of %, compared with US$ 15 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Icotinib industry is evaluated to reach US$ 28 million in 2029. The CAGR will be 8.6% during 2024 to 2029.
The Icotinib market is primarily driven by the demand for targeted therapies in the treatment of non-small cell lung cancer (NSCLC). Icotinib is a medication used as a tyrosine kinase inhibitor for patients with advanced NSCLC that carries EGFR mutations. The increasing prevalence of lung cancer, particularly among non-smokers and those with specific genetic mutations, contributes to market growth. Moreover, advancements in personalized medicine and the demonstrated efficacy of Icotinib in improving progression-free survival further propel adoption. However, challenges include managing the cost of targeted therapies and addressing potential drug resistance or adverse effects. Navigating patient access issues, optimizing treatment sequencing, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in lung cancer treatment, collaborations between pharmaceutical manufacturers and oncologists, and comprehensive patient education on the benefits and potential risks of Icotinib treatment while addressing the evolving challenges associated with precision oncology and cancer treatment accessibility.
Report Covers
This report presents an overview of global Icotinib market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Icotinib market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bette Pharma
Segment by Type
250mg
125mg
Segment by Application
Hospital
Drugs Store
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Icotinib plant distribution, commercial date of Icotinib, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Icotinib introduction, etc. Icotinib Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Icotinib
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices